Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor
Copyright 2002 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2002
To the Editor: Considering that Eli Lilly sponsored
the trial by Dr Kroenke and colleagues1
and that their product, fluoxetine, was the least efficacious of the 3 selective
serotonin reuptake inhibitors (SSRIs) evaluated, I am not surprised that the
authors emphasized that all 3 were similarly effective. In fact, the authors
proclaim that the "ARTIST results unequivocally demonstrate the lack of differences
among 3 SSRIs across a broad range of outcomes over 9 months." The results
are anything but unequivocal.
Stopa SF. Is One Selective Serotonin Reuptake Inhibitor Better Than Another?. JAMA. 2002;287(15):1935-1938. doi:10.1001/jama.287.15.1935